Sun Pharma will be responsible for pursuing regulatory approvals in licensed territories where approval has not yet been ...

In den Vereinigten Staaten ist das Präparat als Lerochol durch die FDA zugelassen; diese Marke und der entsprechende Markt ...

Sun Pharmaceutical Industries and LIB Therapeutics Inc. announced an exclusive licensing agreement granting the Indian pharma ...

Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715; together with its subsidiaries and/or associated companies, "Sun Pharma") and LIB Therapeutics ...

Sun Pharma has entered an exclusive agreement with LIB Therapeutics to commercialise Lerodalcibep across markets outside the US and China, gaining access to a US$ 3.7 billion PCSK9 market.

LIB Therapeutics Inc. und Sun Pharmaceutical Industries Limited haben eine exklusive Lizenzvereinbarung bekannt gegeben, die ...

Sun Pharma will be responsible for pursuing regulatory approvals in licensed territories where approval has not yet been obtained. The excluded China territory comprises mainland China, Hong Kong, ...

Pharma sector stocks such as Sun Pharma, Dr Reddy’s, Cipla, Biocon, Shilpa Medicare, Zydus Life and Hester Bio are in focus ...

"Sun Pharma is excited to launch this much-anticipated, osmotic delivery formulation of methylphenidate as a lower-cost ...

Check out top stocks under brokerages' radar heading into trade today.

Lerodalcibep is approved in the EU under the brand name Lyrokaul for the treatment of adult patients with ...

Mumbai-based Sun Pharmaceutical Industries and US-based LIB Therapeutics Inc. have announced an exclusive licensing agreement ...